Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patients adherent and non-adherent to oral calcimimetics.

Journal: Clinical kidney journal
Published Date: Feb 12, 2020

Abstract

BACKGROUND: In dialysis patients, non-adherence to oral cinacalcet adds complexity to the control of secondary hyperparathyroidism. The present study aims to evaluate the use of intravenous calcimimetic, etelcalcetide, in the control of secondary hyperparathyroidism in patients adherent and non-adherent to oral calcimimetics.

Authors

  • Maria Dolores Arenas
    Nephrology Department, Vithas Perpetuo Socorro International, Alicante, Spain.
  • Cristian Rodelo-Haad
    Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/Reina Sofia University Hospital/University of Cordoba, Cordoba, Spain.
  • M Victoria Pendón-Ruiz de Mier
    Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/Reina Sofia University Hospital/University of Cordoba, Cordoba, Spain.
  • Mariano Rodriguez
    Department of Nephrology, Reina Sofia University Hospital, Cordoba, Spain.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals